Companion Diagnostics Marketing: Working with Pharma Partners

Companion Diagnostics Marketing: Working With Pharma Partners

Companion diagnostics (CDx) occupy a unique position at the intersection of pharmaceutical development and in vitro diagnostics. These tests identify patients who are most likely to benefit from a specific therapy, enabling the kind of precision medicine that improves outcomes, reduces adverse events, and increasingly defines how drugs are prescribed. For diagnostics companies developing and marketing companion diagnostic products, the commercial strategy is unlike any other segment of the medical device industry.

Companion diagnostics marketing involves a complex web of stakeholders: pharmaceutical partners, oncologists, pathologists, laboratory directors, hospital administrators, payers, and patients. The marketing strategy must align with the pharma partner's drug launch timeline, support the clinical workflow in which the test is ordered and performed, and build awareness among the clinicians who ultimately decide whether to test their patients.

This guide covers the strategies and tactics that drive success in companion diagnostics marketing, from building effective pharma partnerships to reaching the clinicians and laboratories that order and perform these tests. Whether you are marketing a tissue-based CDx, a liquid biopsy companion diagnostic, or a next-generation sequencing panel with multiple CDx claims, these principles will help you build a marketing program that maximizes the commercial potential of your product.

Understanding the Companion Diagnostics Ecosystem

Before diving into marketing tactics, it is essential to understand the unique dynamics of the companion diagnostics market. CDx products exist within an ecosystem that is fundamentally different from standalone diagnostic products.

The Pharma-Diagnostics Relationship

Every companion diagnostic is tied to a specific drug or class of drugs. This relationship creates both opportunities and constraints for your marketing strategy. On the opportunity side, the pharma partner's drug launch creates built-in demand for your test and often comes with co-marketing resources and funding. On the constraint side, your marketing must align with the pharma partner's messaging, regulatory approvals, and commercial strategy.

The most successful CDx companies build deep collaborative relationships with their pharma partners and treat the drug-diagnostic pair as a single commercial entity. This means joint marketing planning, coordinated messaging, shared clinical education initiatives, and aligned commercial incentives.

Regulatory Framework

Companion diagnostics are regulated by the FDA as Class III medical devices requiring premarket approval (PMA) or, in some cases, as Class II devices through the 510(k) pathway. The regulatory status of your CDx has significant implications for your marketing claims and promotional activities.

Your marketing must be consistent with the approved indications and intended use of your CDx product. This includes the specific biomarker(s) tested, the specimen type(s) validated, and the clinical decision that the test result informs. Any marketing claims that go beyond the approved indications risk regulatory enforcement.

The Clinical Workflow

Understanding the clinical workflow for companion diagnostic testing is critical for effective marketing. The workflow typically involves an ordering clinician (usually an oncologist or specialist), a pathology laboratory that performs the test, and the clinician who interprets the result and makes the treatment decision.

Each participant in this workflow has different information needs, different decision criteria, and different barriers to adoption. Your marketing must address all of them.

Key Stakeholders in Companion Diagnostics Marketing

Companion diagnostics marketing requires engaging multiple stakeholders simultaneously. Each one plays a different role in the testing and treatment decision.

Pharmaceutical Partners

Your pharma partner is your most important stakeholder. The success of your CDx is directly tied to the success of the drug it supports. Work closely with the pharma partner's commercial team to develop joint marketing plans, co-branded materials, and coordinated launch activities.

Key areas of collaboration include joint medical education initiatives, co-branded clinical resources, shared KOL engagement, coordinated congress and conference strategy, and aligned messaging on the drug-diagnostic pair.

Oncologists and Prescribing Physicians

The prescribing physician is the person who decides whether to order the companion diagnostic test. In oncology, which is the largest CDx market, this is typically the medical oncologist or hematologist-oncologist. Their primary concern is whether testing their patient will inform a better treatment decision.

Marketing to oncologists should emphasize the clinical evidence linking test results to treatment outcomes, the guideline recommendations supporting testing, and the practical logistics of ordering the test. Oncologists are busy clinicians who need clear, actionable information about when to test, what the results mean, and how to apply them to treatment decisions.

Pathologists and Laboratory Directors

Pathologists and laboratory directors are responsible for performing the companion diagnostic test and reporting results. They care about the analytical performance of the test, specimen requirements, turnaround time, laboratory workflow, and reimbursement.

Marketing to pathology and laboratory audiences should provide detailed technical information about assay performance, specimen handling requirements, quality control procedures, and laboratory setup. Technical white papers, validation guides, and implementation support resources are particularly valued by this audience.

Hospital Administrators and Health System Executives

For CDx tests performed in health system laboratories, administrators and executives influence adoption decisions. They care about reimbursement, operational impact, and how testing aligns with institutional precision medicine initiatives.

Payers and Access Stakeholders

Reimbursement and coverage are critical for CDx adoption. If payers do not cover the test, patients will not get tested, and the drug will not get prescribed. Your marketing strategy should include health economics and outcomes research (HEOR) that demonstrates the value of testing to payers, including the clinical and economic impact of identifying appropriate patients for targeted therapy.

Building Your CDx Marketing Strategy

A companion diagnostics marketing strategy must coordinate multiple messages across multiple audiences, all aligned with the pharma partner's drug commercialization timeline. Here is how to structure your approach.

Pre-Launch Phase

The pre-launch phase begins 12 to 18 months before anticipated regulatory approval. During this period, focus on building the clinical evidence base, engaging KOLs, and preparing your marketing infrastructure.

• Publish clinical validation data in peer-reviewed journals
• Present at major oncology and pathology conferences
• Build your KOL network and advisory board
• Develop your digital marketing infrastructure including website, SEO, and content
• Coordinate with your pharma partner on joint pre-launch activities
• Engage payers with health economic evidence

Launch Phase

The CDx launch is typically coordinated with the drug launch. This creates a unique marketing dynamic where the diagnostics company and pharma company are both launching simultaneously and need to deliver a coordinated message.

Your launch marketing should include coordinated announcements with the pharma partner, educational campaigns targeting prescribing physicians, laboratory implementation support for pathology labs that will offer the test, payer engagement with coverage and coding guidance, and digital marketing campaigns to build awareness.

Post-Launch Growth Phase

After launch, your marketing focus shifts to driving testing rates, expanding geographic availability, and building the evidence base for the drug-diagnostic pair. Key post-launch marketing activities include ongoing medical education, clinical data dissemination, patient identification programs, laboratory network expansion, and real-world evidence generation.

Digital Marketing for Companion Diagnostics

Digital marketing plays an increasingly important role in companion diagnostics commercialization. Here are the digital strategies that drive the best results.

SEO and Content Marketing

Build an SEO-optimized digital presence that serves both physician and laboratory audiences. Target keywords related to your biomarker, the clinical condition, and the drug-diagnostic relationship. Create content that addresses the clinical questions physicians have about testing and the technical questions laboratory professionals have about implementation.

Your content strategy should include clinical guideline summaries, biomarker testing algorithms, laboratory implementation guides, case studies demonstrating clinical utility, and patient identification resources. Each piece of content should be optimized for search and designed to capture leads for your sales and medical affairs teams.

Medical Education Campaigns

Medical education is a primary marketing vehicle for companion diagnostics. Digital education campaigns including webinars, online CME programs, and interactive clinical tools help build awareness among prescribing physicians and pathologists.

Partner with your pharma partner on joint medical education initiatives that address the entire drug-diagnostic pathway, from patient identification and testing to treatment selection and monitoring.

Physician and Lab Portal Development

Build digital portals that make it easy for physicians to understand testing options and for laboratories to implement your assay. A physician portal might include testing algorithms, result interpretation guides, and test ordering resources. A laboratory portal might include technical specifications, validation protocols, and implementation checklists.

Working Effectively With Pharma Partners

The pharma-diagnostics relationship is the foundation of companion diagnostics marketing success. Here are best practices for building productive partnerships. For comprehensive guidance on these partnership dynamics, see our medical device marketing guide.

Aligning Commercial Interests

The pharma company's primary interest is maximizing drug sales. Your primary interest is maximizing test utilization. These interests are aligned when testing leads to drug prescribing, but they can diverge when testing identifies patients who should not receive the drug, or when the pharma company develops interest in alternative diagnostic approaches.

Build commercial alignment by establishing shared metrics and goals, creating joint commercial plans, and maintaining regular strategic alignment meetings at the executive level.

Co-Marketing and Resource Sharing

Pharma partners often provide significant co-marketing resources for companion diagnostics, including funding for medical education, joint promotional materials, and support for conference activities. Maximize the value of these resources by integrating them into your overall marketing plan rather than treating them as separate activities.

Managing Multiple Pharma Relationships

If your diagnostic platform supports multiple companion diagnostic claims across different drugs and pharma partners, you need to manage each relationship carefully. Ensure that your marketing activities for one drug-diagnostic pair do not conflict with another, and maintain clear boundaries between pharma partnerships to avoid commercial and regulatory complications.

Patient Identification Programs

One of the most impactful marketing initiatives for companion diagnostics is building systematic patient identification programs. These programs help clinicians identify patients who should be tested, addressing one of the primary barriers to testing rate improvement.

Develop clinical decision support tools that integrate with electronic health record systems. These tools can flag patients with specific diagnoses, disease stages, or clinical characteristics that indicate they should be tested with your CDx product. When a physician opens a patient chart, the CDS tool prompts them to consider biomarker testing, removing the reliance on the physician remembering to order the test.

Create patient identification algorithms and share them through clinical pathway partners, health system pharmacy and therapeutics committees, and tumor board educational programs. The more you can embed your testing into standard clinical pathways, the higher your testing rates will be.

Work with your pharma partner to develop field-based patient identification programs where medical science liaisons (MSLs) and specialty representatives educate physicians about testing eligibility criteria. These programs can be particularly effective for new indications where physician awareness of testing recommendations is still building.

Real-World Evidence Generation

Real-world evidence (RWE) is becoming increasingly important in companion diagnostics marketing. While pivotal clinical trial data forms the foundation of your evidence base, real-world data from commercial use demonstrates how your CDx performs in routine clinical practice and adds credibility to your marketing claims.

Build a systematic approach to collecting and analyzing real-world data from your installed laboratory network. Track testing rates by geography and institution type, turnaround times in practice, specimen adequacy rates, the percentage of tested patients who receive the companion therapy, and clinical outcomes for patients who were tested and treated based on results.

Publish real-world evidence in peer-reviewed journals and present at conferences. This data supplements your pivotal trial results and provides the practice-based evidence that many physicians find most compelling when making testing decisions.

Liquid Biopsy CDx Marketing

Liquid biopsy companion diagnostics represent a rapidly growing segment that requires specialized marketing approaches. Unlike tissue-based CDx products, liquid biopsy tests use a simple blood draw rather than a surgical biopsy specimen, creating fundamentally different workflow advantages and marketing messages.

Marketing liquid biopsy CDx products should emphasize the non-invasive nature of the test, the ability to test patients who lack adequate tissue specimens, the potential for serial monitoring of treatment response and resistance, faster turnaround times compared to tissue-based testing, and the ability to capture tumor heterogeneity that a single tissue biopsy might miss.

Address the limitations honestly as well. Liquid biopsy sensitivity may be lower than tissue-based testing for certain biomarkers, and not all payers cover liquid biopsy CDx at the same level as tissue-based alternatives. Transparent communication about both strengths and limitations builds credibility with the oncology community.

Overcoming Barriers to CDx Adoption

Despite the clinical value of companion diagnostics, several barriers can slow adoption. Your marketing strategy should proactively address these obstacles.

Testing Rate Challenges

Even when guidelines recommend biomarker testing, actual testing rates are often lower than they should be. Studies consistently show that a significant percentage of eligible patients are never tested, representing both a clinical failure and a commercial opportunity for CDx marketers. The reasons for undertesting are multifaceted and include lack of physician awareness of testing guidelines, tissue insufficiency or inadequate specimen quality, long turnaround times that delay treatment decisions, logistical barriers in the ordering process, and uncertainty about how to interpret and act on test results.

Your marketing should address each of these barriers with targeted solutions and resources. For awareness gaps, invest in physician education programs and clinical pathway integration. For specimen issues, develop specimen collection guides and consider liquid biopsy alternatives. For turnaround time concerns, publish your laboratory's median turnaround time and compare it to competitors. For ordering logistics, simplify the test ordering process with online portals, pre-printed order forms, and dedicated customer service support.

Reimbursement Barriers

Inadequate reimbursement can prevent laboratories from offering companion diagnostic tests. When laboratories cannot recover the cost of performing a CDx assay, they are unlikely to invest in the instrumentation, training, and validation required to offer it. This creates a gap between clinical guidelines that recommend testing and the practical availability of the test at the laboratory level.

Work with payers proactively to secure coverage and reimbursement before or at the time of launch. Develop comprehensive reimbursement support resources that help laboratories navigate the coding and billing process, including CPT code selection guidance, Medicare and commercial payer coverage summaries by plan and region, sample prior authorization requests with clinical justification language, and appeal letter templates for denied claims that include supporting clinical evidence.

Laboratory Implementation Barriers

Laboratories face practical challenges in implementing new CDx assays, including instrumentation requirements, personnel training, validation processes, and quality management. Provide comprehensive implementation support that reduces these barriers and accelerates laboratory adoption.

Measuring CDx Marketing Success

Companion diagnostics marketing success is measured differently than other medical device marketing because your ultimate metric is testing rate, the percentage of eligible patients who are tested with your CDx product.

Key Metrics

• Testing rate: Percentage of eligible patients tested, tracked by geography, institution type, and physician segment
• Test volume: Total test volume and growth rate by laboratory and region
• Laboratory coverage: Number and geographic distribution of laboratories offering your test
• Physician awareness: Surveyed awareness of biomarker testing recommendations and your specific CDx product
• Time to result: Average turnaround time from specimen collection to result reporting
• Marketing-attributed volume: Test volumes attributable to specific marketing campaigns and channels

Geographic Expansion and Global CDx Marketing

Companion diagnostics marketing often involves geographic expansion as you build laboratory coverage across regions. Each new geography presents unique challenges including varying regulatory requirements, different payer landscapes, and varying levels of physician awareness about biomarker testing.

Develop a prioritized geographic expansion plan that considers several factors: the patient population with the target condition in each region, the availability of treating physicians who prescribe the companion therapy, the laboratory infrastructure capable of performing your test, and the payer landscape including coverage status and reimbursement rates.

For regions where laboratory infrastructure is limited, consider establishing send-out testing partnerships with reference laboratories that can perform your CDx assay for hospitals and clinics that lack in-house capability. Marketing to support send-out testing should emphasize the simplicity of specimen collection and shipping, the turnaround time from specimen receipt to result reporting, and the logistical support your company provides for specimen management.

International CDx marketing adds additional complexity including country-specific regulatory approvals, health technology assessments, local KOL networks, and cultural differences in treatment decision-making. Work with local marketing partners and country-specific medical affairs teams to adapt your global marketing strategy for each market.

Sales Force Effectiveness and Medical Affairs Coordination

CDx marketing must work hand-in-hand with both sales and medical affairs functions. The marketing team creates awareness and generates demand, the sales team converts that demand into laboratory contracts and test orders, and medical affairs provides the scientific credibility and clinical education that supports both functions.

Develop marketing programs that directly support sales force effectiveness. Create call decks, leave-behind materials, and digital sales tools that field representatives can use in their interactions with oncologists, pathologists, and laboratory directors. Build territory-specific marketing programs that address the unique competitive dynamics and customer needs in each geography.

Coordinate closely with medical affairs to ensure that marketing messages are scientifically accurate and that promotional activities do not cross into territory that should be handled by MSLs under medical affairs governance. The line between promotional and scientific communication is carefully regulated in the pharmaceutical and diagnostics industries, and maintaining this distinction is essential for compliance.

Building a CDx Brand Identity

While companion diagnostics are tied to specific drugs, your CDx product still needs its own brand identity. A strong brand creates recognition among physicians, pathologists, and laboratory professionals, and it differentiates your CDx from potential competitive testing options.

Build your brand around the clinical impact of accurate, reliable biomarker testing. Position your CDx as the trusted standard for identifying patients who will benefit from targeted therapy. Develop consistent visual branding, messaging, and communications that reinforce this positioning across all channels and touchpoints.

Consider how your CDx brand relates to your corporate brand. If your company has multiple CDx products across different biomarkers and therapeutic areas, you may want a branded house approach where all products share the corporate brand identity, or a house of brands approach where each CDx has its own distinct brand. The right approach depends on your portfolio strategy and the degree of association you want between products.

The Future of Companion Diagnostics Marketing

The companion diagnostics market is evolving rapidly. Several trends will shape CDx marketing strategies in the coming years, including the expansion of liquid biopsy CDx products, the growth of multi-biomarker panels and comprehensive genomic profiling, the increasing use of real-world data in CDx evidence generation, and the emergence of new biomarker-drug combinations across therapeutic areas beyond oncology.

Companies that build flexible, scalable marketing capabilities today will be best positioned to capitalize on these trends and grow their companion diagnostics businesses. A specialized medical device marketing partner with experience in the diagnostics and pharma interface can help navigate the unique complexities of this market.